UA040009 IL-21 Protein, Human
- 公司名稱 杭州斯達特生物科技有限公司
- 品牌 Starter/斯達特
- 型號 UA040009
- 產(chǎn)地 江蘇 南京
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時間 2025/7/16 11:58:15
- 訪問次數(shù) 42
聯(lián)系方式:王修明13774214275 查看聯(lián)系方式
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!
IL-21 (another common gamma chain cytokine) that is produced primarily by CD4+ T cells of the TFH lineage has a range of functions, including the promotion of apoptosis, proliferation, and gain of effector function in B cells, T cells, NK cells, and DC. After BMT, TFH cells drive marginal zone B cell expansion and aberrant B cell development. These B cells produce alloantibodies in a Bruton's tyrosine kinase (BTK)–dependent manner, and these antibodies are now established as making a critical contribution to cGVHD. IL-21 also induces IL-10 production and can thus have both regulatory and proinflammatory roles, depending on the other cytokines present. IL-21R deficient animals and specific blocking antibodies have been used to assess the role of IL-21 in GVHD, confirming it has a pathogenic role in the GI tract (with receptor-deficient animals experiencing less GI-specific GVHD). The use of IL-21 blocking mAb used in a xenogeneic mouse model (with NOD/SCID/γc?/- recipients) has demonstrated a decrease in CD8+ T cells and an increased proportion of Tregs. This group also demonstrated local protein expression of IL-21 in the GIT and skin, but not serum. Neutralization of IL-21 represents a promising therapeutic strategy to prevent and treat cGVHD that now requires investigation in a clinical study.